Genfit bags FDA breakthrough tag on route to phase 3 in PBC

Genfit has secured FDA breakthrough designation for elafibranor in primary biliary cholangitis (PBC) on the back of midstage data. The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.